Cabaletta Bio (NASDAQ:CABA – Get Rating)‘s stock had its “buy” rating reiterated by equities researchers at Mizuho in a report released on Friday, Benzinga reports. They currently have a $10.00 target price on the stock. Mizuho’s target price suggests a potential upside of 23.46% from the stock’s previous close.
CABA has been the topic of several other reports. Evercore ISI upped their price objective on shares of Cabaletta Bio from $14.00 to $18.00 in a research note on Thursday, February 16th. Wells Fargo & Company upped their target price on shares of Cabaletta Bio from $4.00 to $14.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. HC Wainwright upped their target price on shares of Cabaletta Bio from $11.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday. Finally, Morgan Stanley upgraded shares of Cabaletta Bio from an “equal weight” rating to an “overweight” rating and upped their target price for the stock from $3.00 to $16.00 in a research report on Friday, January 27th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $14.17.
Cabaletta Bio Stock Up 4.5 %
Shares of Cabaletta Bio stock opened at $8.10 on Friday. Cabaletta Bio has a 1-year low of $0.59 and a 1-year high of $12.88. The firm’s 50-day moving average price is $9.67 and its two-hundred day moving average price is $5.54.
Hedge Funds Weigh In On Cabaletta Bio
Cabaletta Bio Company Profile
Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
- Get a free copy of the StockNews.com research report on Cabaletta Bio (CABA)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Cabaletta Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabaletta Bio and related companies with MarketBeat.com's FREE daily email newsletter.